New Treatment Approaches and Prognostic Biomarkers for Advanced Chronic Obstructive Pulmonary Disease and Potential Associated Cardiovascular Risks

Omar Khorfan^{1

2}, Samer Alsamman^{1

2}, Hawazin Abbas^{1

2}, Abdulghani Sankari^{1

2

3}

Affiliations

¹ 1 Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan.
² 2 Department of Medicine, Detroit Medical Center, Detroit, Michigan; and.
³ 3 Department of Medicine, John D. Dingell VA Medical Center, Detroit, Michigan.

Comment

Omar Khorfan et al. Am J Respir Crit Care Med. 2019.

. 2019 Apr 1;199(7):913-916.

doi: 10.1164/rccm.201804-0659RR.

Omar Khorfan^{1

2}, Samer Alsamman^{1

2}, Hawazin Abbas^{1

2}, Abdulghani Sankari^{1

2

3}

¹ 1 Department of Medicine, Wayne State University School of Medicine, Detroit, Michigan.
² 2 Department of Medicine, Detroit Medical Center, Detroit, Michigan; and.
³ 3 Department of Medicine, John D. Dingell VA Medical Center, Detroit, Michigan.

No abstract available

Comment on

Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD.
Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF; FLAME Investigators. Wedzicha JA, et al. N Engl J Med. 2016 Jun 9;374(23):2222-34. doi: 10.1056/NEJMoa1516385. Epub 2016 May 15. N Engl J Med. 2016. PMID: 27181606 Clinical Trial.
Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort.
Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, Putcha N, Ortega VE, Li X, Barr RG, Carretta EE, Couper DJ, Cooper CB, Hoffman EA, Kanner RE, Kleerup E, O'Neal WK, Paine R 3rd, Peters SP, Alexis NE, Woodruff PG, Han MK, Meyers DA, Bleecker ER; SPIROMICS investigators. Hastie AT, et al. Lancet Respir Med. 2017 Dec;5(12):956-967. doi: 10.1016/S2213-2600(17)30432-0. Epub 2017 Nov 13. Lancet Respir Med. 2017. PMID: 29146301 Free PMC article.
Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease: A Nested Case-Control Study.
Wang MT, Liou JT, Lin CW, Tsai CL, Wang YH, Hsu YJ, Lai JH. Wang MT, et al. JAMA Intern Med. 2018 Feb 1;178(2):229-238. doi: 10.1001/jamainternmed.2017.7720. JAMA Intern Med. 2018. PMID: 29297057 Free PMC article.

1. Hastie AT, Martinez FJ, Curtis JL, Doerschuk CM, Hansel NN, Christenson S, et al. SPIROMICS investigators. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5:956–967. - PMC - PubMed
1. Singh D, Edwards L, Tal-Singer R, Rennard S. Sputum neutrophils as a biomarker in COPD: findings from the ECLIPSE study. Respir Res. 2010;11:77. - PMC - PubMed
1. Bafadhel M, Pavord ID, Russell REK. Eosinophils in COPD: just another biomarker? Lancet Respir Med. 2017;5:747–759. - PubMed
1. Bafadhel M, McKenna S, Terry S, Mistry V, Reid C, Haldar P, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011;184:662–671. - PubMed
1. Pavord ID, Chanez P, Criner GJ, Kerstjens HAM, Korn S, Lugogo N, et al. Mepolizumab for eosinophilic chronic obstructive pulmonary disease. N Engl J Med. 2017;377:1613–1629. - PubMed